Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus Zimberelimab for Stage III–IVa Nasopharyngeal Carcinoma
ChiCTR2200066669Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zimberelimab in nasopharyngeal carcinoma (NPC), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Objective response rate. Started Dec 2022; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200066669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066669.